Core Insights - The article discusses the 10 best stocks with the most insider ownership to buy now, highlighting a market environment influenced by geopolitical factors and inflation concerns [1][4]. Insider Activity - There has been a significant increase in insider selling, with corporate executives selling over $21 billion in equities in March 2026, while insider buying was limited to approximately $2.3 billion [2]. Market Analysis - A Reuters analysis indicated that there were instances where investors anticipated outcomes of major White House rulings, raising concerns about potential information leaks and the fairness of markets [3]. Company Performance - Rocket Companies, Inc. (NYSE:RKT) has been highlighted as a stock with substantial insider ownership, with adjusted EPS expectations for 2026 and 2027 set at $0.75 and $1.10, respectively [8]. - Keefe, Bruyette & Woods upgraded Rocket Companies to Outperform, raising its price target from $20 to $22, citing recent share declines and improvements in revenue mix as factors for sustainable long-term earnings potential [9]. - HEICO Corporation (NYSE:HEI) reported earnings per share of $1.35, exceeding forecasts, with revenue of $1.18 billion, and highlighted solid performance in its engine business [11]. - HEICO's Flight Support Group achieved balanced organic growth, with parts sales and repair and overhaul sales both increasing by 13% [12].

Core Viewpoint - Kosmos Energy, an independent oil and gas company, is focusing on deep-water exploration and production, leveraging its technical expertise and asset portfolio to drive growth and efficiency in underexplored regions [1][2]. Company Overview - Kosmos Energy operates primarily in deep-water oil and gas exploration and production, with key assets located offshore Ghana, Equatorial Guinea, the U.S. Gulf of Mexico, and gas development projects offshore Mauritania and Senegal [2]. - The company has a competitive edge due to its focused asset portfolio and proven basin exploration strategy [1]. Recent Transaction - Director Adebayo Ogunlesi reported an open-market purchase of 3,157,895 shares of Kosmos Energy for approximately $6.0 million [6]. - This purchase increased Ogunlesi's direct common stock holdings by 173.87%, raising his position from 1,816,289 to 4,974,184 shares, more than doubling his exposure to the company [4]. Market Performance - Kosmos Energy's stock price has surged approximately 198% year-to-date, with a 35% increase since March 10, reaching $2.71 per share [7]. - The stock is currently trading at about 8 times forward earnings, indicating potential value [9]. Strategic Developments - The government of Ghana extended Kosmos Energy's license to drill for oil until 2040, and the company has sold assets in Equatorial Guinea to concentrate on its operations in Ghana [9]. - Kosmos Energy is guiding for a significant increase in production in fiscal 2026 [9]. Public Offering Context - The recent stock purchase occurred alongside a public offering of common stock at $1.90 per share, which was a significant discount compared to the market price at the time [8].

Company Overview - Photronics operates a business model focused on supplying critical photomask technology and services for semiconductor wafers and display substrates, generating revenue primarily from semiconductor and display manufacturers [1][5]. Recent Insider Transaction - On January 7, Lee Kang Jyh, a director of Photronics, executed an open-market sale of 10,000 shares at $34.83 per share, which aligns with his recent median sale size and resulted in a 2.19% reduction in his direct holdings, leaving him with over 445,000 shares [2][4][6]. Market Performance Context - The transaction occurred when Photronics shares were priced at $34.83, reflecting a 41.65% increase over the prior 12 months, indicating the sale was executed during a period of elevated share value [2]. - The company reported full-year fiscal 2025 revenue of $849.3 million, down 2% year over year, while GAAP net income increased to $136.4 million from $130.7 million the previous year [7]. Strategic Insights - Management highlighted strength in the U.S. market and increased diversification from Korea, validating investment plans in the country [7]. - Despite the insider sale, the overall performance of Photronics suggests that long-term investors should not be distracted, as shares have outperformed the S&P 500's roughly 18% gain over the same period [7].

Company Overview - Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and immunoscience conditions, aiming to address significant gaps in current treatment paradigms [1] - The company operates with a strategy centered on scientific innovation and targets unmet medical needs in healthcare [1][5] Insider Activity - Chief Accounting Officer George Clark purchased 17,000 shares of Biohaven on November 17, 2025, marking his first open-market purchase in two years [4] - Following this transaction, Mr. Clark's total ownership increased to 85,595 shares, representing approximately 0.062% of Biohaven's outstanding shares [2][3] Stock Performance - The shares were acquired at a weighted average price of $8.52, while the market closed at $8.27 on the transaction date and was at $9.45 as of November 18, 2025 [3] - The stock recently hit a 52-week low of $7.48 on November 11, 2025, a significant drop from its high of $47.75 nearly a year ago [6] Financial Performance - Biohaven reported a net loss of $173.4 million in Q3, an increase from $160.3 million in the prior year, and ended the quarter with approximately $264 million in cash and investments [8] - To strengthen its balance sheet, the company implemented an equity offering that generated about $200 million [8] Regulatory Challenges - The U.S. FDA rejected Biohaven's request for approval of its lead drug, troriluzole, on November 4, 2025, prompting the company to announce cost-cutting measures shortly thereafter [7] - As an early-stage biotechnology company, Biohaven does not currently generate revenue and relies on regulatory approval to begin selling its drugs [7]